These healthcare stocks have long-term and profitable growth runways.

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Since last year, DexCom ( DXCM +5.54%) has faced a series of issues that have sunk its stock price. The medical device ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been ...

Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...